Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06067698 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Alpha Lipoic Acid in Ulcerative Colitis

StatusCompleted
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial completed Study completion date changed from estimate of Apr 1, 2025 to Aug 1, 2025 · Interventions: "Mesalamine" and "Placebo" (Drug), "Mesalamine" and "alpha-lipoic acid" (Drug) to "Mesalamine" and "Placebo" (Drug), "Mesalamine" and "alpha-lipoic acid" (Drug) · Eligibility criteria expanded, about 18 words · 2 more Show 5 more changesShow less
    • Study completion date changed from estimate of Apr 1, 2025 to Aug 1, 2025
    • Interventions: "Mesalamine" and "Placebo" (Drug), "Mesalamine" and "alpha-lipoic acid" (Drug) to "Mesalamine" and "Placebo" (Drug), "Mesalamine" and "alpha-lipoic acid" (Drug)
    • Eligibility criteria expanded, about 18 words
    • Secondary endpoints: details revised at 4 of 4 entries
    • Site details revised
  2. Trial status: Not Yet Recruiting to Recruiting Primary completion date: Jul 1, 2024 to Apr 1, 2025 · Completion date: Oct 1, 2024 to Apr 1, 2025v3 Show 2 more changesShow less
    • Primary completion date: Jul 1, 2024 to Apr 1, 2025
    • Completion date: Oct 1, 2024 to Apr 1, 2025
  3. Interventions: Mesalamine + Placebo (Drug), Mesalamine + alpha-lipoic acid (Drug) to "Mesalamine" and "Placebo" (Drug), "Mesalamine" and "alpha-lipoic acid" (Drug) Secondary endpoints revised (4)v2 Show 1 more changeShow less
    • Secondary endpoints revised (4)

    See this version in full on ClinicalTrials.gov ↗

  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study aims at evaluating the efficacy and safety of alpha-lipoic acid as adjuvant therapy to mesalamine in patients with mild to moderate ulcerative colitis due to its effect as anti-oxidant and anti-inflammatory drug which can help to improve disease.
Trial Details
NCT Number NCT06067698
Lead Sponsor Tanta University
Conditions Ulcerative Colitis, Ulcerative Colitis (UC)
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov